RRD International, a specialised product development company, has appointed Dr Ulrich Thienel as its new chief development and medical officer (CDMO).
As CDMO, Thienel will provide scientific, development and management leadership to PDTs formed between RRD and its partners, as well as play a key role in developing strategies to expand RRD’s business.
In addition, Thienel will be involved in the advancement of RRD’s ClearPath Development subsidiary, which helps bring companies, products and investors together.
Prior to joining RRD, Thienel served as vice president of asset strategy at Takeda.
Scott Tarrant, president of RRD International, said: “Dr Thienel is an ideal match for RRD and its growth needs as we continue to increase the scale and scope of our product development programmes.
“In his previous role at Takeda, Dr Thienel oversaw a team of more than 300 staff and was responsible for a large portfolio of assets. This extensive therapeutic and management experience combined with his strategy-driven approach to development offers an invaluable asset to RRD and our partners.”